GW Pharmaceuticals receives positive NICE recommendation for Epidyolex for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

GW Pharmaceuticals plc announces that two of its medicines, Epidyolex (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK�s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England. This represents the first-time any plant-derived cannabis-based medicine has been recommended by NICE for use on the NHS. Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Nabiximols, reviewed as part of NICE�s evaluation of cannabis-based medicinal products (CBMPs), has been considered cost effective for the treatment of spasticity due to multiple sclerosis. The inclusion of nabiximols in NICE guidelines comes as part of the comprehensive evaluation of the clinical and cost-effectiveness of CBMPs. Nabiximols has been approved by medicines regulators in more than 25 countries around the world. Nabiximols was approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2010 and is marketed in the UK by GW�s commercial partner, Bayer.